ASP Isotopes Inc.

AI-generated fair value estimate for this company.

Method: 10-year DCF with an explicit ramp schedule rather than a constant growth rate: forecast free cash flow of approximately -$60M, -$20M, $30M, $120M, and $210M in years 1-5 (reaching the low end of management's own guided $300-700M 2031 EBITDA target as enrichment facilities scale and reach commercial shipments), then 8% growth for two years tapering to 5% for years 6-10; 12% discount rate for facility build-out and financing risk; 4% terminal growth; approximately $14.6M net debt ($269.5M debt less $254.9M cash) subtracted; 153.31M shares outstanding.

Reasoning: ASP Isotopes is in an early commercial build-out phase where cash flow is currently deeply negative but management has provided a specific longer-term EBITDA target as facilities scale, so an explicit multi-year ramp anchored to the conservative low end of that guidance was used instead of a simple constant-growth extrapolation of the current loss-making base.